ViewPoint was developed in 2014, and focuses on non-surgical treatments to correct protein misfolding in lenses, which can lead to presbyopia and cataracts.
Visus, which is currently conducting two phase 3 trials to study eyedrops to treat presbyopia, will use ViewPoint’s assets to advance development of other treatments for age-related vision loss, according to a news release from the company.
“The ViewPoint acquisition provides an extensive library of potent drug candidates with highly desirable pharmaceutical properties for ocular delivery,” Rhett Schiffman, MD, Visus’ co-founder and chief medical officer, said in a Sept. 28 press release.
